热门资讯> 正文
2024-09-19 20:06
GLMD: 60% | Galmed Pharmaceuticals Plans To Broaden Its Drug Development Activities, Consisting Of Two Additional Programs Over The Next Two Years
EWTX: 42% | Edgewise Therapeutics Announced Top-line Data Of EDG-7500 From The Phase 1 Trial In Healthy Subjects And The Single-dose Arm Of Phase 2 CIRRUS-HCMtrial In Patients With Obstructive Obstructive Hypertrophic Cardiomyopathy
XCUR: 271% | Exicure shares are trading higher after the company announced it received an extension from the Nasdaq Hearings Panel.